Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Aggressive Urate Lowering Needed for Gout

Kathy Holliman  |  Issue: July 2010  |  July 1, 2010

In gout, the uric acid crystals activate complement by the alternative pathway, but also by the classical pathway through the accumulation of immunoglobulin. The crystals interact with macrophages, produce cytokine interleukin-1, and then generate other cytokines.

Dr. Pillinger said that uric acid has multiple and complex effects on cells, depending on their concentration and whether they are soluble or crystalline. Some effects have apparently been—and perhaps still are—evolutionarily advantageous. “Understanding uric acid biology may permit more rational targeting of future antiinflammatory and antihyperuricemic agents,” Dr. Pillinger concluded.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Kathy Holliman is a medical journalist based in New Jersey.

References

  1. Becker MA, MacDonald P, Chefo S, Jackson RL. Baseline characteristics of gout subjects influence orate-lowering efficacy during febuxostat and allopurinol treatment. #704. Presented at the ACR Annual Scientific Meeting. Oct. 19, 2009. Philadelphia.
  2. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62:1060-1068.
  3. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: The Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007:57:109-115.
  4. Vazquez-Mellado J, Garcia CG, Vazquez SG, et al. Metabolic syndrome and ischemic heart disease in gout. J Clin Rheumatol. 2004;10:105-109.
  5. Rho YH, Choi SJ, Lee YH, et al. The prevalence of metabolic syndrome in patients with gout: A multicenter study. J Korean Med Sci. 2005;20:1029-1033.
  6. DeVera M, Rahman MM, Bhole V, et al. The independent impact of gout on risk for coronary heart disease among elderly women: A population-based study. #1509. Presented at the ACR Annual Scientific Meeting. Oct. 20, 2009. Philadelphia.

Page: 1 2 3 | Single Page
Share: 

Filed under:Clinical Criteria/GuidelinesConditionsGout and Crystalline Arthritis Tagged with:Cardiovascular diseaseGoutPaintherapyTreatmenturate-lowering therapies

Related Articles

    Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4

    October 14, 2019

    Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.

    Difficult Gout

    July 1, 2007

    “Grandpapa’s Torments” was the Rodnan Commemorative Gout Print featured at the 2005 ACR/ARHP Annual Scientific Meeting.

    Gout, Glucose Metabolism and Obesity: A Case Review

    November 2, 2014

    New research explores association between hyperurecimia and gout with metabolic derangement

    Lost and found

    Understanding the Role of Uric Acid in Gout

    September 6, 2022

    From the first substantial argument in the 19th century that uric acid played a role in gout, it took about 100 years for the medical community to accept its role in triggering acute inflammatory gout attacks. Two papers, both published in 1962, helped demonstrate the link between uric acid and acute gout attacks, quickly opening…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences